TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03436160
Drug: WR909388
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg Carbon-14 radio labeled WR909388 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
Study: NCT01798979
Drug: GLPG0634
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
Study: NCT03436160
Drug: WR909390
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg Carbon-14 radio labeled WR909309 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
Study: NCT01607385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID, repeat doses
Study: NCT01607385
Drug: GSK1614235
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID, co-dosed BID with last dosing day of active/placebo repeat doses
Study: NCT02015988
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01651936
Drug: MK-8457 100 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8457 100 mg dosed orally BID
Study: NCT01651936
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX dosed at the stable dose received upon study entry
Study: NCT01618396
Drug: Sedation drug (Propofol and Midazolam)
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Septic patients, after intubation, were initially sedated with propofol. During the second day of mechanical ventilation, propofol infusion was interrupted. When the patient awoke, the sedative drug was changed to midazolam. Sedation target was a Ramsay Scale score of 4 to 5.
Study: NCT00676975
Drug: Traditional Chinese Medicine Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 8 weeks
Study: NCT03907267
Drug: Taurine Solution
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine Solution
Study: NCT00531622
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration, capsules
Study: NCT03964402
Drug: intervention treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: intervention treatment (any)
Study: NCT02390063
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic cyclophosphamide (50mg bd)
Study: NCT00119119
Drug: pentoxyphilline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01304043
Drug: chemotherapies protocols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV
Study: NCT03627611
Drug: Liothyronine
Normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 months
Study: NCT01405794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile Water No Silver
Study: NCT04962451
Drug: Placebo+ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo loading dose on day 1 (2 tablets, matched with ticagrelor 90mg), followed by placebo twice daily (matched with ticagrelor 90mg) Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
Study: NCT00976690
Drug: Azathioprine OR Mesalazine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine : 2mg/kg/day Mesalazine : 4g/day
Study: NCT02593383
Drug: Adapalene + Clindamycin Hydrochloride
Normalized name: adapalene / benzoyl peroxide / clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% Adapalene + 1% Clindamycin Hydrochloride
Study: NCT02593383
Drug: Adapalene + Clindamycin Hydrochloride
Normalized name: adapalene / benzoyl peroxide / clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% Adapalene + 2% Clindamycin Hydrochloride
Study: NCT00703183
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered as a single dose, orally
Study: NCT01306123
Drug: Nascobal nasal spray (cyanocobalamin, USP)
Normalized name: vitamin B12 Nasal Spray [Nascobal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intranasal administration
Study: NCT01306123
Drug: Vitamin B12-ratiopharm N, injection solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single intramuscular administration
Study: NCT01139788
Drug: LY2624587
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-900 mg, administered intravenously, weekly for a minimum of one (1) 28 day cycle.~If patients are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days).
Study: NCT01921647
Drug: YH4808
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01921647
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00497666
Drug: Rosiglitasone (retrospective observation)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02247414
Drug: Low Molecular Weight Heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
Study: NCT02024295
Drug: Ademethionine
Normalized name: Racemethionine
DrugBank: Racemethionine (DB13972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
Study: NCT02024295
Drug: Polyene Phosphatidyl choline
Normalized name: lecithin
DrugBank: Lecithin (DB15834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
Study: NCT02024295
Drug: Ademethionine
Normalized name: Racemethionine
DrugBank: Racemethionine (DB13972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: after 6 weeks of core treatment stage, then ademethionine 1000mg bid or qd orally for 42 weeks
Study: NCT00676845
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage form: tablet; frequency: daily; duration: 3 weeks
Study: NCT04510298
Drug: SP-624
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT04510298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT01783340
Drug: Azithromycin capsules
Normalized name: Azithromycin Capsules
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin capsules will be administered at each immunization
Study: NCT01783340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be administered at each immunization
Study: NCT02153905
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
Study: NCT00597051
Drug: ARD-0403
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06106074
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral
Study: NCT02293837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects assigned to this group will receive placebo intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight \<30kg) every 4 weeks for 24 weeks.
Study: NCT05448586
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of balanced anesthesia including opioids during anesthesia for gynecologic cancer surgery
Study: NCT01288209
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg capsule taken by mouth once daily for 12 or 24 weeks.
Study: NCT02040090
Drug: Active rabies vaccine (US-FDA approved)
Normalized name: rabies virus vaccine flury-lep strain Injection [RabAvert]
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
Study: NCT03082833
Drug: AZD2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2014 is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
Study: NCT00583466
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be injected under the lesion to create submucosal cushion
Study: NCT01732549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food
Study: NCT00351377
Drug: Enteric-coated Mycophenolate Sodium
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily.
Study: NCT00047723
Drug: minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03809039
Drug: MT-6345 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT-6345 Placebo
Study: NCT01494714
Drug: JNJ 10229570-AAA 1.2% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
Study: NCT01494714
Drug: Color-matched vehicle in a cream formulation containing 0 mg of JNJ 10229570-AAA
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
Study: NCT00513487
Drug: Dust mite extract, Fluticasone, Methacholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dust mite extract, Fluticasone, Methacholine
Study: NCT01675245
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Velcade will be administered as per the recommended regimen. (Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks)
Study: NCT02258464
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 6 cycles of saline injection
Study: NCT02885662
Drug: CS-3150
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-3150 2.5 to 5.0 mg , orally.
Study: NCT01755520
Drug: Placebo - Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02388152
Drug: Lu AF20513, medium dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02388152
Drug: Lu AF20513, high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02388152
Drug: Lu AF20513, double high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01863641
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo similar to intervention (shape, color and design) 1 oral unit daily.
Study: NCT00376415
Drug: Lessertia Fructescens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
Study: NCT00376415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received an identical placebo capsule twice daily for 3 months.
Study: NCT02274090
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel consist of drug without the active component.
Study: NCT02671188
Drug: GSK3050002
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 3 mL glass vial contains white to off-white lyophilized powder which requires reconstitution with sterile water for injection.Prepared as 100 milligrams per milliliter (mg/mL) solution; lower concentrations prepared by dilution with 0.9% weight by volume (w/v) sodium chloride Injection for infusion.
Study: NCT02671188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% sodium chloride) will be used as placebo.
Study: NCT00389272
Drug: Ibuprofen, acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00220961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets similar to pioglitazone tablets - 1 tablet/day
Study: NCT02710994
Drug: CDFR0209
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release omeprazole 40 mg and sodium bicarbonate 1,100 mg
Study: NCT00179738
Drug: CC5013
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05138484
Drug: experimental group 10% mouthwash of M. sylvestris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: To each patient was delivering a 150 ml bottle with the corresponding mouthwash. The indications for posology were: rinse with 10 ml of mouthwash for 1 minute in the mouth, every 12 hours for 7 days. To the follow-up of the intervention, was made telephone calls at least once a day to remember the rinse.
Study: NCT00420784
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00092053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT00092053
Drug: ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tablets
Study: NCT04162002
Drug: Restylane® Lyft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filler Injection
Study: NCT03836859
Drug: rhNGF 20μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Eye (For subjects randomized to rhNGF group) Day 1: One drop instilled into study eye (35 μL, corresponding to 0.70 μg of rhNGF).~Day 2, 3, 4, 5, 6: One drop six times a day (every 2h) into study eye (210 μL, corresponding to 4.20 μg of rhNGF).~Total dose in the study eye will be 31 drops (1085 μL, equivalent to 21.7 μg rhNGF) over 6 days.
Study: NCT02737020
Drug: Rhodiola
Normalized name: RHODIOLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola rosea 200mg pill up to four times a day
Study: NCT02737020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: up to four times a day
Study: NCT00556374
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mg zoledronic acid administered at a constant infusion rate
Study: NCT03640247
Drug: Non-narcotic group regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Narcotic Group. Receives only alternating acetaminophen and ibuprofen
Study: NCT03640247
Drug: Narcotic group regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narcotic Group: Alternating acetaminophen and ibuprofen, with a prescription of 10 tablets oxycodone (or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg) for break through pain.
Study: NCT00760344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYR-472 placebo-matching tablets, orally, once daily with lifestyle modification and/or metformin therapy for up to 12 weeks.
Study: NCT01857726
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transarterial chemoembolization (TACE) with adriamycin
Study: NCT03866369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose at D-1
Study: NCT03866369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily oral dose during 14 days
Study: NCT03473210
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: ampicillin 2g IV every 6hours for 48 hours, followed by erythromycin 250mg every 6hours for 5days
Study: NCT03473210
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexamethasone 8mg intramuscular every 12hours for 48 hours i.e. in four divided doses
Study: NCT01937169
Drug: Levodopa tablet
Normalized name: Levodopa Tablets
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01937169
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00070993
Drug: creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01647542
Drug: TAK-875 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 placebo-matching tablets
Study: NCT02638103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to fremanezumab will be administered as per schedule specified in the respective arms.
Study: NCT02294474
Drug: SAR342434
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by subcutaneous (SC) injection, immediately (within 5 -10 minutes) before meals intake. Dose adjusted to achieve 2 hour post prandial glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
Study: NCT02871505
Drug: Benzathine Penicillin G
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04268537
Drug: Thymosin+standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin 1.6 mg sc qd, last for 5 days. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study: NCT02265666
Drug: BIIL 284 BS tablet C
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01774045
Drug: PDC-1421
Normalized name: chlorpheniramine maleate / dihydrocodeine bitartrate / phenylephrine hydrochloride Oral Solution [Despec-PDC]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01774045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03575676
Drug: SOM3355 100mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03575676
Drug: SOM3355 200mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01800708
Drug: Prednisolone syrup
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04737213
Drug: SGM-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorescence guided surgery
Study: NCT03575676
Drug: Placebo BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03714568
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)
Study: NCT00095823
Drug: Antidepressant + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
Study: NCT04282590
Drug: Placebo/TRK-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for oral solution
Study: NCT02225821
Drug: Cephalozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Cephalozin
Study: NCT00101335
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02177253
Drug: Placebo Inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02177253
Drug: Placebo Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06250543
Drug: AbobotulinumtoxinA 300 UNT
Normalized name: abobotulinumtoxinA 300 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 evenly distributed intradetrusor injections, 1 ml per site, were performed
Study: NCT06250543
Drug: IncobotulinumtoxinA 100 UNT
Normalized name: incobotulinumtoxinA 100 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 evenly distributed intradetrusor injections, 1 ml per site, were performed
Study: NCT00518713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets; orally; daily for 15-18 weeks
Study: NCT00971997
Drug: Lispro Mix 50/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously once daily for 16 weeks, twice daily for 16 weeks, and three times daily for 16 weeks dependent on glycemic control.
Study: NCT00997256
Drug: Neurapas® balance (Herbal product (Hypericum, Passionflower, Valerian))
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 2 tablets / day over 3 days
Study: NCT02470689
Drug: Diacerin cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerin tablet solubule in ultraphil cream
Study: NCT00990951
Drug: Senna alexandrina and associations
Normalized name: Senna alexandrina seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs: Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub~1 tablet PO twice a day
Study: NCT01888874
Drug: GLPG0634
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG0634 capsules.
Study: NCT01888874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules.
Study: NCT04508855
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from direct oral anticoagulants to low molecular weight heparin
Study: NCT00334542
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24-28 weeks of simvastatin
Study: NCT01673022
Drug: IC Green
Normalized name: ELECTRIC GREEN BARB TRANSGENIC WHOLE (GB2011 RDNA CONSTRUCT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC Green
Study: NCT01384812
Drug: dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous injection 0.4 μgr/kg/min for 25 min
Study: NCT00519636
Drug: FPNS
Normalized name: Fluticasone Propionate and Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fluticasone propionate nasal spray
Study: NCT00519636
Drug: placebo FFNS
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo nasal spray matching fluticasone furoate nasal spray
Study: NCT00519636
Drug: placebo FPNS
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo nasal spray matching fluticasone propionate nasal spray
Study: NCT00979953
Drug: ADL5747
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00979953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no